Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a ...

Amgen Inc. (NASDAQ:AMGN) has sold its office campus in Deerfield, Illinois, for $151 million. The buyer is an entity tied to ...

Amgen Inc. (NASDAQ:AMGN)’s experimental drug dazodalibep met the main goal of a late-stage trial for Sjögren’s disease. After ...

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.

By Christy Santhosh Sept 22 (Reuters) - Amgen said on Tuesday its experimental drug to treat an autoimmune disease that ...

Morgan Stanley met with Amgen management after Novartis's pelacarsen trial failure. The bank sees a real edge for AMGN's ...

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment ...

Amgen (AMGN) stock drops after a phase 3 trial failure for a heart drug from Novartis (NVS) and Ionis Pharma (IONS). BMO Capital Markets downgrades. Read more here.

Major market indexes such as the S&P 500 declined in the first few months of the year, but have since rebounded significantly. In contrast, biotech giant Amgen (AMGN +2.11%) started the year strong, ...

Amgen drops after Novartis’ pelacarsen Phase 3 miss, pressuring olpasiran’s thesis amid patent cliffs. Click here to read an ...

Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against ...